The therapeutic landscape of Glioblastoma Multiforme (GBM) is rapidly shifting, driven by intense research and a growing understanding of the tumor's immune evasion mechanisms. Historically reliant on the Stupp protocol (radiation and temozolomide), the market is now experiencing an infusion of novel modalities, signaling a move towards more biologically rational and patient-specific...